How to Pay for Ketamine Therapy: 10 Ways to Afford Treatment (2026)

Updated April 11, 2026

The biggest barrier to ketamine therapy isn't clinical — it's financial. A standard six-session IV infusion course costs $2,400–$4,800 out of pocket, and most insurers still refuse to cover generic ketamine for psychiatric use.

But patients have more options than they realize. From Spravato insurance coverage and HSA/FSA accounts to employer-sponsored psychedelic benefits and free clinical trials, at least ten distinct pathways exist to make treatment affordable.

This guide breaks down every one — with current pricing, named programs, and practical next steps — so patients can build a realistic financial plan before their first appointment.

---

1. Insurance Covers Spravato Broadly, but Generic Ketamine Remains Largely Excluded

Every major U.S. commercial insurer now covers Spravato (esketamine nasal spray) for treatment-resistant depression (TRD) and major depressive disorder with acute suicidal ideation. A 2025 analysis of 18 major commercial insurers found 100% had written coverage policies for Spravato. The catch: all require prior authorization, and the requirements are strict.

Insurer-by-Insurer Overview

Standard prior authorization requirements across most insurers include a confirmed MDD or TRD diagnosis, documentation of at least two failed antidepressant trials (each at adequate dose for 6–8+ weeks), treatment at a REMS-certified clinic, and concurrent use of an oral antidepressant. Though the FDA approved Spravato as monotherapy for TRD in January 2025, which may eventually relax this requirement.

UHC typically approves for 12 months initially. Cigna approves for 6 months for TRD.

Spravato Costs: With vs. Without Insurance

Without insurance, each Spravato session runs $700–$1,500 (medication plus facility/monitoring fees), and induction-phase costs can reach $4,700–$8,000+ in the first month alone.

With insurance, typical copays drop to $10–$50 per session after the deductible. Under coinsurance plans, expect roughly $140–$240 per session. Janssen's SPRAVATO withMe Savings Program can reduce the medication copay to as low as $10 per treatment, with up to $8,150 in annual savings — but this is only available to commercially insured patients, not those on Medicare, Medicaid, TRICARE, or VA plans.

For uninsured or low-income patients, the Johnson & Johnson Patient Assistance Foundation provides Spravato free of charge to qualifying individuals, with income-based eligibility criteria (verify current thresholds directly with the foundation).

The Rare Exceptions for IV Ketamine Coverage

Generic IV ketamine for psychiatric use is classified as "experimental" or "investigational" by nearly all insurers since it lacks FDA approval for mental health indications. However, a few documented exceptions exist:

• Blue Cross Blue Shield of Massachusetts maintains a formal written policy (Policy 087) covering IV ketamine for TRD with criteria similar to Spravato — the first major commercial insurer to do so.
• Mass General Brigham Health Plan considers IV ketamine "medically necessary for selected individuals with treatment-resistant major depression or severe suicidal ideation" (policy updated October 2025).
• Kaiser Permanente (San Francisco Bay Area) — some patients have reported receiving IV ketamine coverage on a case-by-case basis, but no published policy document has been confirmed and Kaiser generally classifies IV ketamine as off-label. Coverage should not be assumed.

Superbills and Out-of-Network Reimbursement

Patients who pay out-of-pocket for IV ketamine can request a superbill — a detailed itemized invoice — from their clinic and submit it to their insurer for out-of-network reimbursement. Typical reimbursement rates range from 20–50% of costs, depending on the plan's deductible and "usual and customary" rates, though reimbursement is never guaranteed.

Key CPT codes clinics use on superbills:

• 96365 — IV infusion, initial (up to 1 hour) — the primary billing code for IV ketamine
• 96366 — Each additional hour of sequential infusion (add-on)
• 96372 — IM injection (for intramuscular ketamine)
• 99202–99205 / 99212–99215 — Evaluation and management (new/established patient visits)
• G2082 / G2083 — Spravato-specific HCPCS codes for self-administration plus 2-hour observation
• J3490 with U4 modifier — Unclassified drug code used for ketamine; however, billing experts recommend removing J codes from superbills, as reimbursement is minimal ($1–2) and may flag the claim

Regulatory note: In June 2025, 53 major insurers (including UHC, Aetna, Cigna, Humana, Kaiser, and the BCBS Association) pledged to streamline prior authorization processes, with some changes effective January 1, 2026. This could ease Spravato access going forward.

---

2. HSA and FSA Funds Can Pay for All Forms of Ketamine Therapy

Ketamine therapy is eligible for both HSA and FSA spending when prescribed to treat a diagnosed medical condition. The IRS does not specifically mention ketamine in any publication, but the legal basis is clear: IRS Publication 502 defines qualified medical expenses as "amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease," and Publication 969 confirms that HSA-qualified expenses follow the same definition.

All modalities qualify — IV, IM, oral/sublingual, and Spravato — because the IRS applies a "medical purpose" test, not a drug-approval test. Off-label prescribing is standard medical practice and does not disqualify an expense. Critically, unlike marijuana (which violates federal law and is therefore HSA/FSA ineligible), ketamine is a legally prescribed Schedule III drug and falls squarely within IRS rules.

Documentation Best Practices

While some HSA/FSA administrators process ketamine charges without question, others may request a Letter of Medical Necessity (LMN). Patients should proactively obtain one from their prescriber that includes their diagnosis with ICD-10 codes, an explanation of medical necessity, description of the treatment, and the provider's credentials and signature.

Additionally, keep all itemized receipts showing dates, provider name, amounts, and descriptions of services.

When ketamine is NOT HSA/FSA eligible: Claims may be denied if the purpose is framed as "wellness," "optimization," or "personal growth" rather than treatment of a diagnosed condition, or if receipts lack sufficient detail.

While no specific written guidance from major HSA administrators (Optum Bank, Fidelity, HealthEquity) was found explicitly addressing ketamine, numerous clinics across the country confirm they routinely accept HSA and FSA cards.

---

3. CareCredit Leads Financing, but Watch for Deferred-Interest Traps

CareCredit is the most widely accepted third-party financing option at ketamine clinics. CareCredit operates across 275,000+ healthcare providers nationally, and it appeared on the payment pages of a large majority of clinic websites surveyed, including multi-location chains like Complete Ketamine Solutions, Stella (formerly Field Trip Health), and Transcend Ketamine.

The critical CareCredit caveat: CareCredit offers promotional "No Interest if Paid in Full" periods of 6, 12, 18, or 24 months — but uses deferred interest. If any balance remains when the promotional period ends, all accrued interest from the purchase date is charged retroactively at 32.99% APR. The CFPB has flagged this structure as a consumer harm. Patients who cannot guarantee full repayment within the promotional window may face significant unexpected charges.

For longer-term financing, CareCredit offers reduced APR plans: 17.90% for 24 months, 18.90% for 36 months, and 19.90% for 48 months (on purchases of $1,000+).

Alternative Financing Options

• Advance Care Card — Matches patients with credit cards offering true 0% APR for 12–14 months (unlike CareCredit's deferred interest). Used by numerous clinics alongside CareCredit.
• Cherry — Newer healthcare fintech offering true 0% APR (not deferred interest) with instant approval. Used by 50,000+ providers, though not yet widely verified at ketamine clinics specifically.
• Walnut — Used by Stella/Field Trip Health; offers 0% APR with 24-month repayment plans (rate varies by credit score).
• Prosper Healthcare Lending — Offers medical loans at 8.99%–35.99% APR. The standalone "Prosper Healthcare Lending" brand has been folded into Prosper's general personal loan platform, which still offers healthcare-specific financing for $2,000–$50,000. Verify current availability before applying.

In-house payment plans are offered by some clinics. Documented examples include Ketamine Uplift, which offers 0% APR financing at $325/month for 12 months ($3,900 total), and Klarisana, which offers financing through Healthcare Finance Direct.

---

4. Sliding Scale Clinics and Nonprofits Exist but Remain Small in Scale

Sliding scale pricing is not the norm at for-profit ketamine clinics, but a growing number of mission-driven practices offer income-based pricing. Confirmed examples include Alchemy Community Therapy Center (Bay Area, CA), a nonprofit that uses a cross-subsidy model where higher-paying clients fund lower-income access; Ember Health (NYC), which reduces its standard $550/session fee to $330/session for eligible patients; and Transcend Ketamine (Austin/San Antonio), which offers sliding-scale IV infusion pricing plus $50 off per session for veterans, first responders, teachers, and nurses.

Nonprofit and Charitable Programs

• The Serenity Foundation (Chicago) — 501(c)(3) sponsoring ketamine infusions for patients with financial need. Pledges that 90%+ of donated funds go directly to treatment costs. Patients apply online at serenityfoundation usa.org.
• Ketamine Research Foundation (KRF) — Runs an "Access to Care" program providing funding for patients who cannot afford ketamine-assisted psychotherapy.
• Treatment Assistance Fund, Inc. (TAFI) (Wisconsin) — Specifically for low-income Wisconsinites with MDD and suicidal thinking, including help with transportation costs.
• Thank You Life — Awards scholarships for psychedelic-assisted therapy including KAP; partners with vetted clinics like PVD Ketamine & Wellness (Providence, RI).
• Help & Heal Mental Health Fund — Offers small "Community Connection Treatment Grants" for patients pursuing alternative therapies like ketamine after documenting failed conventional treatments.
• IRPC (Institute for Rural Psychedelic Care) (Humboldt, CA) — Covers the cost of ketamine medication sessions for Medicare and Medi-Cal patients through donations.

These nonprofits fill a vital gap, but their capacity is limited by philanthropic funding — demand almost certainly exceeds supply. Patients unable to access these programs frequently turn to GoFundMe campaigns, typically seeking $2,000–$3,600 to cover an initial infusion series.

For Spravato specifically, Janssen's Patient Assistance Program (PAP) provides medication free of charge for up to one year to qualifying patients with limited income or no insurance.

---

5. Clinical Trials Offer Free Treatment — and Some Even Pay Participants

Multiple institutions are actively recruiting participants for free ketamine and psilocybin therapy through clinical trials. This is one of the most underused pathways to access.

Ketamine Trials Currently Recruiting

The NIMH/NIH in Bethesda, MD runs several ketamine studies under Carlos Zarate, Jr., MD. These offer no cost to participate, compensation up to $4,660, and travel expenses covered by NIMH. Current studies include a repeated-dose ketamine and neuroimaging study for MDD (ages 18–65, inpatient 14–20 weeks) and a ketamine + perampanel mechanism study (5-week inpatient). Contact: moodresearch@mail.nih.gov or 1-877-MIND-NIH.

Stanford University is recruiting for a ketamine + buprenorphine trial for suicidal depression (NCT05624268) and a multi-dose ketamine vs. active placebo trial for TRD (NCT01920555). Contact: depressionresearch@med.stanford.edu.

Other notable recruiting ketamine trials include studies at Mayo Clinic (Rochester, MN) examining ketamine and GABA/glutamate in TRD, and a UCSF KARE Trial studying ketamine-assisted psychotherapy for methamphetamine use disorder.

Psilocybin Trials Currently Recruiting

Johns Hopkins Center for Psychedelic & Consciousness Research (Baltimore) has the largest portfolio, with active studies for depression, PTSD, OCD, opioid use disorder, cannabis use disorder, ALS-related distress, and Alzheimer's-related depression (NCT04123314). The University of Washington PsiloStudy (NCT06853912) is recruiting veterans and first responders with co-occurring alcohol use disorder and PTSD, offering up to $550 compensation. Yale has recruiting trials for MDD (NCT06308653), OCD (NCT03356483), and methamphetamine use disorder (NCT04982796).

How to find and qualify: Search ClinicalTrials.gov by condition and intervention, filtering by "Recruiting" status. Also check institutional websites directly — Hopkins (hopkinspsychedelic.org), NIMH (nimh.nih.gov/join-a-study), Stanford (med.stanford.edu/drc/research), and Yale (medicine.yale.edu/psychiatry).

The process typically involves an online pre-screening, a phone interview, an in-person psychiatric evaluation with validated symptom scales, and a possible medication washout period. Proximity to the study site matters — most prefer local participants, though NIMH covers travel nationwide.

There is no guarantee of receiving the active drug versus placebo in randomized trials.

Note: The NIMH website includes a notice that "due to current HHS and NIH restructuring, some content on nimh.nih.gov is not being updated regularly." Contact study teams directly for current status.

---

6. The VA Covers Both Spravato and IV Ketamine for Eligible Veterans

The VA represents one of the most comprehensive pathways to covered ketamine therapy. Per the VA's national protocol guidance (revised October 2025), IV ketamine infusions are available at select VA facilities and through the Veterans Community Care Program for veterans who meet specific criteria: failure of at least 2 antidepressant trials plus one augmentation strategy in the current episode AND 4 total adequate trials in their lifetime, OR hospitalization with TRD and acute suicidal ideation. A PHQ-9 score above 15 within the last 30 days is also required.

Dosing follows a standardized protocol: 0.5 mg/kg IV over 40 minutes, repeated up to twice weekly for 4 weeks during induction, then weekly to monthly for maintenance. Two-hour post-infusion monitoring with ACLS-certified personnel is mandatory.

Spravato is available on a non-formulary basis (equivalent to prior authorization in the civilian system). Veterans who meet criteria can access it through the VA's Clinical Determination and Indication document (CDI Number 00029, effective January 1, 2025).

Community care access is expanding. Veterans more than 40 minutes from a VA facility offering ketamine can be referred to private clinics through Veterans Care Agreements (VCAs). Clinics with confirmed VCAs include Innerbloom Ketamine Therapy (San Luis Obispo, CA), Higher Dimensions of Healing (Carson City, NV), and Avesta Ketamine & Wellness (Tysons, VA). Treatment through these agreements is 100% covered with no out-of-pocket cost for the veteran.

Veteran-Focused Nonprofits Funding Psychedelic Therapy

• Veterans Exploring Treatment Solutions (VETS) — Founded by former Navy SEAL Marcus Capone; provides "Foundational Healing Grants" for veterans and spouses to access psychedelic therapy at vetted facilities (primarily outside the U.S. where treatments are legal). Over 900 veterans served; 93.2% report feeling less depressed (self-reported).
• Heroic Hearts Project — Connects veterans to psychedelic therapy including ayahuasca, psilocybin, ibogaine, and ketamine. Now offers legal psilocybin retreats in Bend and Portland, OR. Over 1,000 veterans served/on waitlist. Each retreat costs approximately $6,500.
• Ketamine Treatment Fund for Veterans — Provides donated funds toward covering ketamine treatment costs.
• Veteran Mental Health Leadership Coalition (VMHLC) — Coalition of 17 veteran-led organizations advocating for expanded access.

VA psychedelic research is accelerating. In December 2024, the VA awarded its first psychedelic therapy research grant since the 1960s — ~$1.5 million for MDMA-assisted therapy for PTSD at Providence and West Haven VA Medical Centers. In November 2025, the VA confirmed expansion of psychedelic trials across nine facilities nationwide.

---

7. Medicaid Coverage Is a Patchwork, and State Psychedelic Programs Are Emerging

A rigorous cross-sectional analysis published August 2025 reviewed Medicaid coverage documents across 165 policy-making entities in all 51 U.S. jurisdictions. The findings paint a fractured picture: only 75 of 165 entities (45.5%) explicitly cover Spravato, with 96% requiring prior authorization. Six jurisdictions have zero coverage entities at all. IV ketamine was covered by just 1 of 165 entities (0.6%), and IM ketamine coverage was zero.

Because managed care organizations control 60.6% of these decision points, two Medicaid beneficiaries in the same state can get opposite coverage decisions depending on their MCO.

Texas updated its Medicaid prior authorization criteria effective May 1, 2025, now covering Spravato as monotherapy for adults with TRD. Medicare Part B covers Spravato at 80% after the $257 deductible (2025) when administered at REMS-certified facilities; it does not cover IV ketamine for psychiatric purposes.

State Psychedelic Programs

Oregon's psilocybin program (Measure 109) has served approximately 16,000 clients since launching in summer 2023, with over 37,000 psilocybin products sold. However, the program faces a stark affordability crisis: sessions cost $1,000–$3,000+, insurance does not cover them, and the average client income is approximately $136,000–$164,000 — nearly double Oregon's median household income. About one-quarter of service centers that opened have already shut down, and no legislative funding was allocated for 2025–27.

Colorado's Natural Medicine program began accepting license applications in December 2024 and had 34 state-licensed healing centers operational by early 2026. Sessions range from $1,500 to $4,500, and insurance does not cover them. The program is currently limited to psilocybin and psilocin; the Natural Medicine Advisory Board may recommend adding DMT, ibogaine, and mescaline after June 1, 2026.

No state mental health department was found to formally include generic ketamine in its standard treatment offerings, and no state-level grants specifically for ketamine therapy were identified.

---

8. At-Home Telehealth Ketamine Costs 60–80% Less, but Tradeoffs Are Real

The at-home ketamine market has matured rapidly, with several providers now offering treatment at a fraction of in-clinic prices. Here is how the major players compare:

Joyous stands out as the most affordable option at $129/month (as low as $89/month with financial assistance), but it uses sub-psychedelic "psycholytic" doses — the evidence base for this daily low-dose approach is less robust than for standard therapeutic doses. Better U offers the lowest macro-dose pricing at $88–100/session, with financing through Affirm available at ~$45/month. Mindbloom launched a subcutaneous injection option in January 2025, with 81% of clients reportedly preferring it over sublingual tablets.

None of these providers accept insurance directly, but most provide superbills for out-of-network reimbursement and accept HSA/FSA cards.

Key Tradeoffs Patients Should Understand

Safety: IV infusions in a clinic allow real-time vital monitoring and immediate dose adjustment or cessation if adverse effects occur. At-home sublingual medication, once consumed, cannot be adjusted. Most at-home programs require a sitter/peer treatment monitor. A peer-reviewed study of 11,441 Mindbloom patients found low adverse reaction rates (less than 5%) and no serious adverse events, which is reassuring — but patients with active suicidal ideation, complex medical histories, or cardiovascular concerns are better suited to clinical settings.

Bioavailability and dosing: IV ketamine has 100% bioavailability with precise titration. Sublingual/oral routes deliver only 10–30% bioavailability with variable absorption. This is why at-home doses appear higher on paper but deliver less drug to the brain. The therapeutic mechanism (NMDA receptor blockade triggering neuroplasticity) is the same regardless of route.

Efficacy: IV ketamine has the strongest randomized controlled trial evidence. However, real-world at-home data is encouraging — Mindbloom's published data shows a 62.8% response rate and 32.6% remission rate, consistent with lab-based IV results.

DEA telehealth rules — a looming uncertainty: All at-home ketamine providers operate under COVID-era telemedicine flexibilities that allow practitioners to prescribe Schedule III controlled substances via telehealth without any prior in-person visit. These flexibilities have been extended four times and are currently valid through December 31, 2026. The DEA proposed a "Special Registration" rule (Docket No. DEA-407) in January 2025 that would create a permanent framework, but no final rule has been issued. Every at-home ketamine provider's business model depends on resolution of this regulatory uncertainty.

---

9. Employer-Sponsored Psychedelic Benefits Are Nascent but Growing

Enthea is the first and currently only licensed provider of health benefit plans covering psychedelic-assisted therapy as a workplace benefit. Founded in 2022, the Boston-based public benefit corporation offers ketamine-assisted psychotherapy (KAP) as an ancillary employer benefit — similar to dental or vision coverage — at a cost of $30–$200 per employee per year. Coverage includes a full KAP treatment course valued at approximately $5,000, using generic ketamine rather than branded Spravato.

Enthea's flagship client is Dr. Bronner's, the soap company that became the first U.S. employer to offer KAP as a health benefit in January 2022. Results from the first year showed 7% of eligible employees (~22 out of 320) accessed the benefit, with self-reported improvements of 86% for PTSD symptoms, 67% for MDD, and 65% for generalized anxiety — though these figures come from a small, self-selected sample reported by Enthea rather than independent researchers.

Mindbloom also offers at-home ketamine therapy as an employer benefit, with known clients including Kennedy Care (Michigan/Ohio), 15Five (HR tech), and SHIFT (management consulting). A 2023 NFP survey found that 17% of employers said they were investing in psychedelic-assisted clinical therapy solutions.

No major EAP providers have been found to formally include ketamine or psychedelic therapy in standard employee assistance programs as of 2025–2026.

Enthea plans to add psilocybin-assisted therapy in Oregon and Colorado (where it's state-legal) and MDMA-assisted therapy once FDA-approved. If COMPASS Pathways' Phase 3 psilocybin trial results (announced February 2026) lead to FDA approval in late 2026 or early 2027, employer-sponsored psychedelic benefits could expand significantly.

---

10. Ketamine Therapy Is Tax-Deductible — but Clearing the AGI Threshold Is the Real Challenge

Ketamine therapy costs qualify as deductible medical expenses on federal taxes under IRC §213(d). IRS Publication 502 allows deductions for "therapy received as medical treatment" and for fees paid to "psychiatrists, psychologists, and nontraditional medical practitioners." The IRS applies a medical purpose standard — it does not restrict deductions to FDA-approved uses, meaning off-label ketamine is treated the same as FDA-approved Spravato for deduction purposes.

The practical hurdle is the 7.5% AGI threshold: only medical expenses exceeding 7.5% of adjusted gross income are deductible, and only if the taxpayer itemizes deductions on Schedule A rather than taking the standard deduction. This threshold was made permanent by the Consolidated Appropriations Act of 2021. For a taxpayer with $100,000 AGI, only medical expenses exceeding $7,500 are deductible.

Given that the 2025 standard deduction is approximately $15,000 for single filers and $30,000 for married filing jointly, the deduction only benefits taxpayers whose total itemized deductions (including medical expenses, state/local taxes, mortgage interest, and charitable contributions) exceed these amounts.

Strategy tip: Patients should consider "bunching" medical expenses — concentrating elective spending into a single tax year to exceed both the 7.5% AGI threshold and the standard deduction. A six-session ketamine series ($2,400–$4,800) combined with other medical expenses may make this viable.

Critical rule: no double-dipping. Expenses paid with HSA or FSA pre-tax dollars cannot also be deducted as medical expenses. Patients should choose the more beneficial option for each expense.

Documentation to keep: Itemized receipts from the clinic (dates, amounts, service descriptions), prescriptions or referrals, diagnosis documentation with ICD-10 codes, superbills with CPT codes, proof of payment, insurance EOBs if applicable, and records of transportation expenses (deductible at 21¢/mile for 2025, plus tolls and parking). The IRS has not issued any ruling or guidance specifically mentioning ketamine — eligibility rests entirely on the general medical expense framework.

---

The Bottom Line

The financial pathway to ketamine therapy depends heavily on which form of treatment a patient pursues. Spravato has the clearest insurance path — every major commercial insurer covers it, and Janssen's savings program can reduce copays to $10. Generic IV ketamine remains almost entirely out-of-pocket, with Massachusetts-based insurers being the notable exception. At-home sublingual ketamine offers the lowest absolute cost (as low as $88–129/month), but its regulatory future hinges on DEA telehealth rules that remain unfinalized.

Three developments could reshape this landscape before the end of 2026: the DEA's permanent telehealth prescribing framework (expected before December 31, 2026), a potential FDA decision on COMPASS Pathways' psilocybin (which could trigger broader insurance coverage of psychedelic therapies), and the continued expansion of employer-sponsored benefits through platforms like Enthea.

Veterans have the most comprehensive coverage pathway through the VA's national protocol and community care agreements. For everyone else, the most pragmatic approach combines HSA/FSA funds for immediate tax savings, superbills for partial out-of-network reimbursement, and financing through Advance Care or CareCredit (with careful attention to deferred interest terms) to spread remaining costs over time.

Find a ketamine clinic near you →

---

This guide is for informational purposes only and does not constitute medical or financial advice. Insurance policies, pricing, and program availability change frequently. Verify all information directly with your provider or insurer before making treatment decisions.